Sergio D. Simon

Porto Alegre, RS, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Survival After Multimodal Treatment for Breast Cancer in Brazil: The Predominant Role of Clinical Stage and Treatment Response.

Survival After Multimodal Treatment for Breast Cancer in Brazil: The Predominant Role of Clinical Stage and Treatment Response.

Journal: Clinical breast cancer

Published: February 26, 2026

Determinants of delayed postoperative radiation therapy in breast cancer patients undergoing neoadjuvant chemotherapy: A subanalysis of the AMAZONA III prospective cohort.

Determinants of delayed postoperative radiation therapy in breast cancer patients undergoing neoadjuvant chemotherapy: A subanalysis of the AMAZONA III prospective cohort.

Journal: Cancer treatment and research communications

Published: May 05, 2025

Germline Genetic Testing in Breast Cancer: Utilization and Disparities in a Middle-Income Country.

Germline Genetic Testing in Breast Cancer: Utilization and Disparities in a Middle-Income Country.

Journal: JCO global oncology

Published: March 07, 2025

Real-World Evidence of Ribociclib Plus Aromatase Inhibitors as First-Line Treatment in Advanced Breast Cancer: The BrasiLEEira Study.

Real-World Evidence of Ribociclib Plus Aromatase Inhibitors as First-Line Treatment in Advanced Breast Cancer: The BrasiLEEira Study.

Journal: JCO global oncology

Published: April 11, 2024

The impact of a breast cancer diagnosis on marital outcomes and factors associated with divorce and separation.

The impact of a breast cancer diagnosis on marital outcomes and factors associated with divorce and separation.

Journal: Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia

Published: October 06, 2023

Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115).

Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115).

Journal: Breast cancer research and treatment

Published: February 12, 2022

Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2- advanced breast cancer: a Brazilian public health care system perspective.

Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2- advanced breast cancer: a Brazilian public health care system perspective.

Journal: Therapeutic advances in medical oncology

Published: January 07, 2022

Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer - Proceedings from breast cancer expert group meeting.

Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer - Proceedings from breast cancer expert group meeting.

Journal: BMC proceedings

Published: June 24, 2021

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE.

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 22, 2020

Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting.

Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting.

Journal: Chinese clinical oncology

Published: April 10, 2020

The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115).

The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115).

Journal: Breast cancer research and treatment

Published: February 29, 2020

Cross-Cultural Validity Study of a Medical Education Leadership Competencies Instrument in Latin American Physicians: A Multinational Study.

Cross-Cultural Validity Study of a Medical Education Leadership Competencies Instrument in Latin American Physicians: A Multinational Study.

Journal: Journal of global oncology

Published: November 27, 2019

Showing 1-12 of 26

Last Updated: 09/26/2026